Inactivación del gen CDKN2A (p16) en cáncer de la vesícula biliar

Background: The CDKN2A gene encodes a cyclin dependent kinase inhibitor, p16, which promotes cell cycle arrest. Methylation of the promoter region trans-criptionally inactivates the gene. Aim: To study the relationship between methylation status of the prometer region of p16 gene, the immunohistoche...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Roa S,Juan Carlos, Vo,Quynh, Araya O,Juan Carlos, Villaseca H,Miguel, Guzmán G,Pablo, Ibacache S,Gilda, de Aretxabala U,Xabier, Roa E,Iván
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2004
Materias:	Gallbladder neoplasms Genes CDKN2 p16 Immunohistochemistry
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872004001100005
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872004001100005
record_format	dspace
spelling	oai:scielo:S0034-988720040011000052005-01-12Inactivación del gen CDKN2A (p16) en cáncer de la vesícula biliarRoa S,Juan CarlosVo,QuynhAraya O,Juan CarlosVillaseca H,MiguelGuzmán G,PabloIbacache S,Gildade Aretxabala U,XabierRoa E,Iván Gallbladder neoplasms Genes CDKN2 Genes p16 Immunohistochemistry Background: The CDKN2A gene encodes a cyclin dependent kinase inhibitor, p16, which promotes cell cycle arrest. Methylation of the promoter region trans-criptionally inactivates the gene. Aim: To study the relationship between methylation status of the prometer region of p16 gene, the immunohistochemical expression of p16 and clinical and morphological features of gallbladder carcinoma. Material and methods: We analyzed the methylation status of the promoter region of the CDKN2A gene in gallbladder adenocarcinomas using methylation specific PCR (MSP). We also used microsatellite markers near the CDKN2A gene to detect allelic imbalance (AI) and examined the tumors by immunohistochemistry (IHC) for p16 expression. Results: Of 38 gallbladder adenocarcinomas analyzed by IHC, 11 cases (29%) were negative for p16 protein. Nine (24%) had methylation of the promoter region of the CDKN2A gene. Twenty nine cases were negative for methylation, but four (14%) of these 29 exhibited AI at one or more of the microsatellite markers. CDKN2A promoter methylation was not associated with microsatellite instability (MSI-H). Conclusions: The inactivation of CDKN2A by methylation and/or deletion might play an important role in gallbladder carcinogenesisinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.132 n.11 20042004-11-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872004001100005es10.4067/S0034-98872004001100005
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Gallbladder neoplasms Genes CDKN2 Genes p16 Immunohistochemistry
spellingShingle	Gallbladder neoplasms Genes CDKN2 Genes p16 Immunohistochemistry Roa S,Juan Carlos Vo,Quynh Araya O,Juan Carlos Villaseca H,Miguel Guzmán G,Pablo Ibacache S,Gilda de Aretxabala U,Xabier Roa E,Iván Inactivación del gen CDKN2A (p16) en cáncer de la vesícula biliar
description	Background: The CDKN2A gene encodes a cyclin dependent kinase inhibitor, p16, which promotes cell cycle arrest. Methylation of the promoter region trans-criptionally inactivates the gene. Aim: To study the relationship between methylation status of the prometer region of p16 gene, the immunohistochemical expression of p16 and clinical and morphological features of gallbladder carcinoma. Material and methods: We analyzed the methylation status of the promoter region of the CDKN2A gene in gallbladder adenocarcinomas using methylation specific PCR (MSP). We also used microsatellite markers near the CDKN2A gene to detect allelic imbalance (AI) and examined the tumors by immunohistochemistry (IHC) for p16 expression. Results: Of 38 gallbladder adenocarcinomas analyzed by IHC, 11 cases (29%) were negative for p16 protein. Nine (24%) had methylation of the promoter region of the CDKN2A gene. Twenty nine cases were negative for methylation, but four (14%) of these 29 exhibited AI at one or more of the microsatellite markers. CDKN2A promoter methylation was not associated with microsatellite instability (MSI-H). Conclusions: The inactivation of CDKN2A by methylation and/or deletion might play an important role in gallbladder carcinogenesis
author	Roa S,Juan Carlos Vo,Quynh Araya O,Juan Carlos Villaseca H,Miguel Guzmán G,Pablo Ibacache S,Gilda de Aretxabala U,Xabier Roa E,Iván
author_facet	Roa S,Juan Carlos Vo,Quynh Araya O,Juan Carlos Villaseca H,Miguel Guzmán G,Pablo Ibacache S,Gilda de Aretxabala U,Xabier Roa E,Iván
author_sort	Roa S,Juan Carlos
title	Inactivación del gen CDKN2A (p16) en cáncer de la vesícula biliar
title_short	Inactivación del gen CDKN2A (p16) en cáncer de la vesícula biliar
title_full	Inactivación del gen CDKN2A (p16) en cáncer de la vesícula biliar
title_fullStr	Inactivación del gen CDKN2A (p16) en cáncer de la vesícula biliar
title_full_unstemmed	Inactivación del gen CDKN2A (p16) en cáncer de la vesícula biliar
title_sort	inactivación del gen cdkn2a (p16) en cáncer de la vesícula biliar
publisher	Sociedad Médica de Santiago
publishDate	2004
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872004001100005
work_keys_str_mv	AT roasjuancarlos inactivaciondelgencdkn2ap16encancerdelavesiculabiliar AT voquynh inactivaciondelgencdkn2ap16encancerdelavesiculabiliar AT arayaojuancarlos inactivaciondelgencdkn2ap16encancerdelavesiculabiliar AT villasecahmiguel inactivaciondelgencdkn2ap16encancerdelavesiculabiliar AT guzmangpablo inactivaciondelgencdkn2ap16encancerdelavesiculabiliar AT ibacachesgilda inactivaciondelgencdkn2ap16encancerdelavesiculabiliar AT dearetxabalauxabier inactivaciondelgencdkn2ap16encancerdelavesiculabiliar AT roaeivan inactivaciondelgencdkn2ap16encancerdelavesiculabiliar
_version_	1718436175294758912

Inactivación del gen CDKN2A (p16) en cáncer de la vesícula biliar

Ejemplares similares